MYRIAD GENETICS PRESENTS RESULTS OF PHASE II TRIAL OF FLURIZAN

Myriad Genetics announced that results of its Phase II clinical trial of Flurizan in patients with mild-to-moderate Alzheimer's disease will be presented as part of the Alzheimer's Association International Conference on Prevention of Dementia, in Washington, D.C.

Patients with mild Alzheimer's disease who received the 800 mg twice-daily dose of Flurizan achieved between 34 percent and 45 percent slowing in decline on the three primary endpoints (activities of daily living, overall function and cognitive ability). A 20 percent or greater slowing in decline is generally regarded as clinically significant.

Flurizan was well-tolerated by Alzheimer's patients and adverse events were generally mild and nonspecific, and they did not differ significantly between placebo and treated groups.